Back to companies

BenevolentAI Ltd: Overview

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Select Item

Related keylists

BenevolentAI Ltd (BenevolentAI) is a drug discovery company. It carries out developing and applying artificial intelligence (AI) to produce new medicines for the treatment of diseases. The company’s pipeline products include BEN-8744 treats ulcerative colitis; BEN-28010 targets glioblastoma multiforme; BEN-34712 is for the treatment of Amyotrophic Lateral Sclerosis (ALS); Parkinson’s Disease treats novel target; Fibrosis targets fibrosis novel target. Benevolent AI’s platform enables scientists to design and develop new treatments for patients, using a large amount of extracted and deduced biomedical information. The company operates in the UK and the US. BenevolentAI is headquartered in London, England, the UK.

 Gain a 360-degree view of BenevolentAI Ltd and make more informed decisions for your business Gain a 360-degree view of BenevolentAI Ltd and make more informed decisions for your business Register your interest
Headquarters Luxembourg
Address 9, rue de Bitbourg, Luxembourg, L-273
Website www.benevolent.com
Telephone 44 20 37819360
No of Employees 248
Industry Pharmaceuticals and Healthcare
Revenue (2023) $9.1M
   
   
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Register your interest

BenevolentAI Ltd premium industry data and analytics

30+

Pipeline Drugs

Identify which of BenevolentAI Ltd’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

8

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for BenevolentAI Ltd’s relevant decision makers and contact details.

7

Catalyst Calendar

Proactively evaluate BenevolentAI Ltd’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

5

Clinical Trials

Determine BenevolentAI Ltd go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

2

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

1

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

Image for loader
Executives
Name Position Board Since Age
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Gain insight into BenevolentAI Ltd key executives to enhance your sales strategy Gain insight into BenevolentAI Ltd key executives to enhance your sales strategy Register your interest
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Why are you leaving?